---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-057825"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:01:14.883022+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q1 net income $34.9M ($0.51 EPS); GSK royalties $60.3M

## Summary
- Net income $34.9M ($0.51 basic EPS) vs $15.8M ($0.23) YoY.
- GSK royalty revenue $60.3M, down from $93.5M YoY due to TRELEGY royalty sale in July 2022.
- Net product sales & license revenue $19.5M ($9M GIAPREZA, $2.5M XERAVA, $8M milestone from China XERAVA approval).
- Repurchased $40.3M of common stock (3.4M shares); paid off $96.2M of 2023 convertible notes.
- FDA advisory committee unanimously voted 12-0 for sulbactam-durlobactam; PDUFA target date May 29, 2023.

## SEC filing metadata
- accession: 0001104659-23-057825
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/0001104659-23-057825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/tm2315160d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-057825
- JSON: https://secwatch.observer/filing/0001104659-23-057825.json
- Plain text: https://secwatch.observer/filing/0001104659-23-057825.txt

## Key facts
- Earnings Releases
  Innoviva, Inc. reported first quarter ended March 31, 2023 results: net income Net income was $34.9 million, EPS $0.51 basic per share.
  - Period: first quarter ended March 31, 2023
  - Net income: Net income was $34.9 million
  - EPS: $0.51 basic per share
  - Result: reported results
  source text: Innoviva, Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1080014/000110465923057825/0001104659-23-057825-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.